Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced positive results from a recently completed phase II clinical study of its ToleroMune(R) cat allergy therapy, which successfully identified the optimal dosing regimens to progress into late-stage development.




Circassia Announces Successful Results From Phase II Clinical Study Of ToleroMune(R) Cat Allergy Therapy



Rox PharmacySponsored by RoxPharmacy.com - Online Pharmacy, an pharmacy online supplies more than 500 quality generic products, free prescription, worldwide shipping.
xanax

Online Canadian Pharmacy canada pharmacy
Share and Enjoy:
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • LinkedIn
  • Live
  • StumbleUpon
  • Yahoo! Buzz
  • Slashdot
  • Technorati
  • MSN Reporter

Related posts:

  1. Circassia Announces Successful Results From Phase II Clinical Study Of ToleroMune(R) Cat Allergy Therapy
  2. Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-Cell Vaccine
  3. Omeros Announces National Institute On Drug Abuse’s Support For Phase 2 Clinical Study In Addiction Program